Natural killer cell educating KIR/HLA combinations impact survival in anti-PD-L1 treated cancer patients
David Roe, Howard Rosoff, Dan Fu Ruan, Zia Khan, Pranay Dogra, Jonathan Carroll, Julie Hunkapiller, Rajat Mohindra, Minu K. Srivastava, Barzin Y. Nabet, G. Scott Chandler, View ORCID ProfileMatthew L. Albert, View ORCID ProfileMark I. McCarthy, View ORCID ProfileIra Mellman, Amir Horowitz, View ORCID ProfileChristian Hammer
doi: https://doi.org/10.1101/2022.12.06.22282592
David Roe
1Genentech; South San Francisco, CA, USA
Howard Rosoff
1Genentech; South San Francisco, CA, USA
Dan Fu Ruan
2Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; New York, NY, USA
Zia Khan
1Genentech; South San Francisco, CA, USA
Pranay Dogra
1Genentech; South San Francisco, CA, USA
Jonathan Carroll
1Genentech; South San Francisco, CA, USA
Julie Hunkapiller
1Genentech; South San Francisco, CA, USA
Rajat Mohindra
3F. Hoffmann-LaRoche; Basel, Switzerland
Minu K. Srivastava
1Genentech; South San Francisco, CA, USA
Barzin Y. Nabet
1Genentech; South San Francisco, CA, USA
G. Scott Chandler
3F. Hoffmann-LaRoche; Basel, Switzerland
Matthew L. Albert
1Genentech; South San Francisco, CA, USA
Mark I. McCarthy
1Genentech; South San Francisco, CA, USA
Ira Mellman
1Genentech; South San Francisco, CA, USA
Amir Horowitz
2Department of Oncological Sciences, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; New York, NY, USA
Christian Hammer
1Genentech; South San Francisco, CA, USA
Article usage
Posted December 07, 2022.
Natural killer cell educating KIR/HLA combinations impact survival in anti-PD-L1 treated cancer patients
David Roe, Howard Rosoff, Dan Fu Ruan, Zia Khan, Pranay Dogra, Jonathan Carroll, Julie Hunkapiller, Rajat Mohindra, Minu K. Srivastava, Barzin Y. Nabet, G. Scott Chandler, Matthew L. Albert, Mark I. McCarthy, Ira Mellman, Amir Horowitz, Christian Hammer
medRxiv 2022.12.06.22282592; doi: https://doi.org/10.1101/2022.12.06.22282592
Natural killer cell educating KIR/HLA combinations impact survival in anti-PD-L1 treated cancer patients
David Roe, Howard Rosoff, Dan Fu Ruan, Zia Khan, Pranay Dogra, Jonathan Carroll, Julie Hunkapiller, Rajat Mohindra, Minu K. Srivastava, Barzin Y. Nabet, G. Scott Chandler, Matthew L. Albert, Mark I. McCarthy, Ira Mellman, Amir Horowitz, Christian Hammer
medRxiv 2022.12.06.22282592; doi: https://doi.org/10.1101/2022.12.06.22282592
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (635)
- Anesthesia (168)
- Cardiovascular Medicine (2418)
- Dermatology (208)
- Emergency Medicine (382)
- Epidemiology (11831)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3792)
- Geriatric Medicine (353)
- Health Economics (641)
- Health Informatics (2427)
- Health Policy (943)
- Hematology (344)
- HIV/AIDS (795)
- Medical Education (372)
- Medical Ethics (105)
- Nephrology (404)
- Neurology (3548)
- Nursing (200)
- Nutrition (531)
- Oncology (1844)
- Ophthalmology (541)
- Orthopedics (223)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (68)
- Pathology (450)
- Pediatrics (1045)
- Primary Care Research (425)
- Public and Global Health (6212)
- Radiology and Imaging (1302)
- Respiratory Medicine (839)
- Rheumatology (381)
- Sports Medicine (327)
- Surgery (409)
- Toxicology (51)
- Transplantation (174)
- Urology (148)